APP
NBIX icon

Avantax Planning Partners’s Neurocrine Biosciences NBIX Stock Holding History

Avantax Planning Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-150
Closed -$18K – 870
2018
Q3 		$18K Buy
+150
New +$17K ﹤0.01% 730
2018
Q2 		– Sell
-10
Closed -$1K – 1017
2018
Q1 		$1K Buy
+10
New +$844 ﹤0.01% 1727

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Avantax Planning Partners's NBIX Position: Q4 2018 in Review

Avantax Planning Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 150 shares — an estimated $18K sold.

Avantax Planning Partners first reported a position in NBIX in Q1 2018 and held it in 2 quarters. The position peaked at $18K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Avantax Planning Partners reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 150 Neurocrine Biosciences shares in Q4 2018, an estimated $18K.
  • Avantax Planning Partners first reported a position in Neurocrine Biosciences in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Neurocrine Biosciences position peaked at $18K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.